Sie sind bereits registriert?
Loggen Sie sich mit Ihrem Universimed-Benutzerkonto ein:
Sie sind noch nicht registriert?
Registrieren Sie sich jetzt kostenlos auf universimed.com und erhalten Sie Zugang zu allen Artikeln, bewerten Sie Inhalte und speichern Sie interessante Beiträge in Ihrem persönlichen Bereich zum späteren Lesen. Ihre Registrierung ist für alle Unversimed-Portale gültig. (inkl. allgemeineplus.at & med-Diplom.at)
A Next-Generation FGR2 Inhibitor for Intrahepatic Cholangiocarcinoma
In biliary cancers that harbor fibroblast growth factor receptor 2 (FGFR2) gene fusions or rearrangements, inhibitors of FGFR2 have significant and often durable activity. Investigators now report the results of an international, industry-sponsored, open-label, phase 2 trial of futibatinib — an oral irreversible inhibitor of FGFR2 — in patients with previously treated advanced biliary cancer with FGFR2 alterations.
Of 798 patients with intrahepatic cholangiocarcinoma undergoing tissue-based screening, 103 with FGFR2 alterations were enrolled and treated with futibatinib (20 mg daily). The median age was 58, most patients (56%) were female, most (78%) had FGFR2 gene fusions as opposed to rearrangements (22%), and most (51%) had received 2 or more prior chemotherapy regimens.
Objective response — the primary outcome — occurred in 42% of patients, and 83% achieved disease control. At a median follow-up of 17.1 months, median duration of response was 9.7 months, and median progression-free survival was 9.0 months. Median overall survival was 21.7 months. In analysis of patients' molecular profiling data, no concurrent gene alterations had an impact on efficacy of therapy. Blood-based circulating tumor DNA testing prior to therapy identified FGFR2 gene fusions and rearrangements in 87% of patients evaluated.
The most common grade 3 or higher treatment-related adverse events included hyperphosphatemia in 30% (with no patients discontinued for this toxicity) and stomatitis, fatigue, and increase in aspartate aminotransferase in 6% to 7% of patients.
Futibatinib is active in patients with biliary cancer harboring FGFR2 gene fusions or rearrangements. Blood-based genomic profiling indicates that this biomarker can be tested in circulating tumor DNA. Futibatinib and the FGFR2 inhibitors infrigratinib and pemigatinib are now approved to treat chemotherapy-resistant biliary cancers with FGFR2 gene alterations. Earlier-line use of these agents, and development of newer-generation FGFR2 inhibitors, are ongoing.
Goyal L et al.
Title: Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma.
Source: N Engl J Med 2023 Jan 19; [e-pub]. (Abstract/FREE Full Text)